Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 10/20 | 0.40 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 2/20 | 0.33 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.32 |
| ▸ | XIAP | P98170 | 1/20 | 0.32 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9877610 | 0.89 | NOS2 (0.45) | MCHR1NOS2NOS3NOS1IDH1 | |
| SCHEMBL22684510 | 0.87 | MCHR1 (0.40) | MCHR1NOS2NOS3 | |
| SCHEMBL19518849 | 0.82 | MCHR1 (0.40) | MCHR1NOS2NOS3NOS1 | |
| SCHEMBL25677207 | 0.80 | MCHR1 (0.44) | MCHR1NOS2NOS3NOS1IDH1 | |
| SCHEMBL19727223 | 0.80 | HTT (0.40) | NOS2NOS3NOS1 | |
| SCHEMBL24971835 | 0.79 | MCHR1 (0.42) | MCHR1NOS2NOS3 | |
| SCHEMBL19518873 | 0.79 | MCHR1 (0.42) | MCHR1NOS2NOS3 | |
| SCHEMBL22684219 | 0.79 | MCHR1 (0.40) | MCHR1NOS2NOS3NOS1 | |
| SCHEMBL23747174 | 0.79 | L3MBTL1 (0.38) | MCHR1IDH1 | |
| SCHEMBL18672443 | 0.78 | MCHR1 (0.41) | MCHR1NOS2NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190290636-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2019-09-26 | — | — | US | disclosed |
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190290636-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | MCHR1 4658/4885NOS2 3566/4885NOS3 2328/4885 |
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | MCHR1 4535/4885NOS2 3381/4885NOS3 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.